Monthly Cost Breakdown: Mounjaro To Wegovy Switch
Can I Change From Mounjaro To Wegovy: Understanding Monthly Cost Differences
Switching from Mounjaro to Wegovy involves understanding distinct monthly cost structures throughout your treatment journey. Wegovy follows a mandatory 16-week dose escalation schedule, with each month presenting different pricing tiers that patients must budget for accordingly. The starter dose at 0.25mg costs £79.99 monthly, providing an accessible entry point for patients transitioning from Mounjaro's pricing structure.
Unlike Mounjaro's dual GIP/GLP-1 receptor approach, Wegovy focuses solely on GLP-1 receptor activation, which may influence both clinical response and cost-effectiveness for individual patients. The monthly progression moves from £79.99 (weeks 1-4) to £94.99 (weeks 5-8), then £99.99 (weeks 9-12), followed by £139.99 (weeks 13-16), before reaching the maintenance dose of £209.99 monthly. This structured approach allows patients to assess tolerance and effectiveness at each stage whilst managing their monthly healthcare budget.
Wegovy Pricing Structure: Complete Monthly Cost Analysis
Our transparent pricing ensures patients can plan their weight management investment when switching from Mounjaro to Wegovy treatment. The Getting Started bundles offer convenience for early treatment phases, with the Intro Duo (0.25mg & 0.5mg) at £169.99 covering your first two months. The Progress Duo continues your journey at £189.99 for months three and four, whilst the Advance Duo supports months four and five at £269.99.
Maintenance dosing at 2.4mg represents the ongoing monthly investment of £209.99, though our Consistency 2.4mg bundle (×2 pens) provides £419.99 for two months of supply. New customers benefit from the FIRST40 discount code applied at checkout, whilst returning patients use DOSE25 for continued savings. These codes are automatically reflected in our listed prices, ensuring transparent budgeting for patients considering the switch from Mounjaro therapy.
Clinical Evidence Supporting The Change From Mounjaro To Wegovy
The STEP clinical trial programme demonstrates Wegovy's effectiveness in weight management, with STEP 1 showing approximately 15% average weight loss at 68 weeks when used alongside diet and exercise. Patients in STEP 2 with type 2 diabetes achieved around 9.6% weight reduction, whilst STEP 3 participants receiving intensive behavioural therapy saw approximately clinically studied weight loss. The recent SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events, adding important clinical context for patients switching treatments.
These results provide evidence-based confidence for patients considering whether they can change from Mounjaro to Wegovy based on clinical efficacy. The sustained weight management shown in STEP 5, with approximately clinically studied weight loss maintained at two years, supports the long-term value proposition of the monthly investment required for Wegovy treatment.
Wegovy Mechanism: GLP-1 Receptor Activation For Weight Management
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to support weight management alongside a reduced-calorie diet and increased physical activity. Unlike Mounjaro's dual GIP/GLP-1 approach, Wegovy's focused GLP-1 mechanism works specifically on brain appetite centres to reduce food cravings and promote satiety after smaller meals. This targeted approach may suit patients who experienced particular side effects with Mounjaro's broader hormonal activity. The once-weekly injection schedule provides consistent appetite regulation throughout the week, supporting sustainable eating pattern changes. As a prescription-only medicine, Wegovy requires careful clinical assessment to ensure appropriate patient selection and monitoring throughout treatment.
Simple Ordering Process: From Assessment To Delivery
Switching from Mounjaro to Wegovy begins with our 3-minute online clinical assessment, designed to evaluate your suitability for treatment transition. Our prescribers typically complete reviews within 3 working days, with express 24-hour service available for urgent requirements. Once approved, your Wegovy prescription ships via next-day delivery using specialist cold-chain transportation to maintain medication integrity. Our GPhC-registered pharmacy (#9012878) ensures all medications meet stringent quality standards from storage through to your doorstep. The streamlined process minimises treatment interruption when transitioning from your previous Mounjaro therapy, maintaining continuity in your weight management programme.
Storage Advantages: Wegovy Vs Mounjaro Practical Benefits
One significant practical advantage when switching from Mounjaro to Wegovy involves storage flexibility, with Wegovy maintaining stability for 6 weeks at room temperature below 30°C once removed from refrigeration. This compares favourably to Mounjaro's 21-day room temperature limit, providing greater convenience for travel, work schedules, or lifestyle flexibility. The FlexTouch pen delivery system offers precise dosing with clear visual confirmation of injection completion. Unopened pens require refrigeration at 2-8°C, but the extended room temperature stability reduces storage anxiety for busy lifestyles. The mandatory dose escalation from 0.25mg through to 2.4mg maintenance allows gradual adaptation to treatment effects whilst monitoring individual response patterns.
Monthly Budgeting Strategy: Planning Your Mounjaro To Wegovy Transition
Successful transition from Mounjaro to Wegovy requires strategic monthly budgeting throughout the 16-week escalation period and ongoing maintenance phase. The escalation costs total £514.97 over four months (£79.99 + £94.99 + £99.99 + £139.99 + £209.99), providing clear financial planning parameters for the initial treatment period. Annual maintenance dosing at £209.99 monthly represents a £2,519.88 yearly investment in your weight management goals, excluding potential bundle savings or promotional periods.
Our bundle options provide supply security whilst managing monthly cash flow, with the Ultimate Stability Trio offering three months of maintenance dosing at £649.99. This approach suits patients who prefer quarterly rather than monthly purchasing cycles, ensuring consistent treatment availability without monthly reordering requirements. The predictable pricing structure eliminates uncertainty about ongoing costs when switching from alternative treatments.
Expert Support: Making The Right Treatment Decision
Both Wegovy and Mounjaro are available from EverydayMeds, allowing our prescribers to help determine which treatment best suits your individual circumstances, medical history, and lifestyle requirements. The decision to change from Mounjaro to Wegovy should consider factors beyond monthly cost, including side effect profiles, injection frequency preferences, and storage convenience requirements. Our clinical team provides ongoing support throughout your treatment journey, monitoring progress and adjusting approaches as needed. The prescription-only medicine status ensures appropriate medical oversight during any treatment transition, prioritising both safety and effectiveness. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and explore whether Wegovy represents the right choice for your weight management goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
